|Assessment Status||Rapid Review Complete|
|Indication||As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.|
|Rapid review commissioned||11/05/2021|
|Rapid review completed||15/06/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that olaparib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations March 2023.